HENGRUI PHARMA (01276) announced that its subsidiary Shanghai Shengdi Pharmaceutical Co., Ltd. recently received an "Acceptance Notice" from the National Medical Products Administration (NMPA), confirming that the company's drug marketing authorization application for a new indication of Adebrelimab injection has been accepted by the NMPA.

Adebrelimab injection is a humanized anti-PD-L1 monoclonal antibody independently developed by the company. It works by specifically binding to PD-L1 molecules to block the PD-1/PD-L1 pathway that leads to tumor immune tolerance, thereby reactivating the immune system's anti-tumor activity to achieve therapeutic effects against tumors.

Similar products available internationally include Atezolizumab (brand name: Tecentriq), Avelumab (brand name: Bavencio), and Durvalumab (brand name: Imfinzi), all approved for sale in the United States. Among these, Atezolizumab and Durvalumab have already received marketing approval in China. Domestically, similar products that have obtained marketing approval include Envafolimab from Alphamab/3D Medicines, Sugemalimab from CStone Pharmaceuticals, and Benmelstobart from Chia Tai Tianqing Pharmaceutical.

According to available data, the combined global sales of Atezolizumab, Avelumab, and Durvalumab reached approximately $9.648 billion in 2024. As of now, the cumulative research and development investment for Adebrelimab injection-related projects amounts to approximately RMB 939 million.